Published in BMC Cancer on December 28, 2012
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int (2015) 1.12
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front Oncol (2013) 1.08
A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One (2014) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med (2013) 0.90
Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget (2016) 0.88
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and progression. Oncol Lett (2014) 0.86
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci (2016) 0.86
Cross Talk between Cancer and Mesenchymal Stem Cells through Extracellular Vesicles Carrying Nucleic Acids. Front Oncol (2016) 0.86
Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer (2015) 0.86
Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One (2015) 0.85
The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med (2015) 0.85
Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis. Expert Rev Mol Diagn (2014) 0.83
MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer. J Ovarian Res (2015) 0.83
Circulating MicroRNAs in gynecological malignancies: from detection to prediction. Exp Hematol Oncol (2014) 0.83
Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer (2016) 0.83
MiR-494 Inhibits Epithelial Ovarian Cancer Growth by Targeting c-Myc. Med Sci Monit (2016) 0.82
Current clinical application of serum biomarkers to detect ovarian cancer. Prz Menopauzalny (2015) 0.82
MiR-1271 Inhibits Ovarian Cancer Growth by Targeting Cyclin G1. Med Sci Monit (2015) 0.81
Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci (2013) 0.81
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci (2015) 0.81
miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res (2016) 0.80
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget (2016) 0.79
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep (2016) 0.79
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol (2016) 0.77
MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer. Oncotarget (2016) 0.77
Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Mol Biotechnol (2016) 0.75
miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. Oncotarget (2016) 0.75
Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer. PLoS One (2016) 0.75
MicroRNA-200 Family Profile: A Promising Ancillary Tool for Accurate Cancer Diagnosis. Am J Ther (2016) 0.75
Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med (2017) 0.75
Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncol Lett (2017) 0.75
MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer (2017) 0.75
Upregulation of miR-520b promotes ovarian cancer growth. Oncol Lett (2017) 0.75
Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer. Oncotarget (2017) 0.75
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 11.46
Cancer of the ovary. N Engl J Med (2004) 11.21
Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (2005) 10.64
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
A comparison of background correction methods for two-colour microarrays. Bioinformatics (2007) 8.59
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res (2008) 5.54
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther (2009) 3.05
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol (2010) 2.80
Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One (2009) 2.68
Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One (2009) 2.55
Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem (2011) 2.42
Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40
Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol (2011) 2.38
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol (2008) 2.30
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci (2011) 2.02
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol (2010) 1.86
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer (2010) 1.73
Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol (2012) 1.58
Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol (2011) 1.30
Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res (1998) 1.22
Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer (2004) 0.88
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Reduced harm or another gateway to smoking? source, message, and information characteristics of E-cigarette videos on YouTube. J Health Commun (2013) 1.67
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol (2006) 1.40
Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab (2002) 1.12
Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett (2007) 1.01
The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Hum Mol Genet (2011) 1.00
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer (2010) 0.99
High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer (2009) 0.99
Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res (2014) 0.98
Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann N Y Acad Sci (2006) 0.97
Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene (2003) 0.94
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab (2008) 0.94
Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res (2004) 0.93
K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma. Clin Endocrinol (Oxf) (2004) 0.92
Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene (2005) 0.90
A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab (2003) 0.90
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer (2010) 0.88
Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Lett (2011) 0.87
Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett (2012) 0.86
The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes. Methods Mol Biol (2010) 0.83
Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocr Relat Cancer (2010) 0.83
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.82
Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells. J Biol Chem (2011) 0.82
Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension (2012) 0.82
Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res (2006) 0.81
Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma. J Surg Res (2008) 0.80
A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J Pediatr (2004) 0.80
Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes Cancer (2014) 0.80
A conservative and fertility preserving treatment for interstitial ectopic pregnancy. Aust N Z J Obstet Gynaecol (2013) 0.80
Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol (2002) 0.80
Factors that may influence the willingness of cancer patients to consent for biobanking. Biopreserv Biobank (2014) 0.79
Mutant AKT1 in Proteus syndrome. N Engl J Med (2011) 0.78
Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunol Res (2014) 0.78
Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway. Gene (2002) 0.76
Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. J Breath Res (2016) 0.76
Diagnosis of Proteus syndrome was correct. Am J Med Genet A (2004) 0.75
Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. J Mol Diagn (2006) 0.75
Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opin Med Diagn (2007) 0.75
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. Horm Cancer (2015) 0.75
Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required. Am J Surg Pathol (2017) 0.75
The effect of disease-associated HRPT2 mutations on splicing. J Endocrinol (2009) 0.75